Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume – Time to Buy?

Takeda Pharmaceutical Company Limited (NYSE:TAK) saw strong trading volume on Wednesday . 853,714 shares traded hands during mid-day trading, a decline of 47% from the previous session’s volume of 1,609,208 shares.The stock last traded at $13.23 and had previously closed at $13.35.

Takeda Pharmaceutical Stock Performance

The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The business’s 50-day simple moving average is $13.51 and its two-hundred day simple moving average is $13.89. The firm has a market cap of $42.19 billion, a price-to-earnings ratio of 22.86, a P/E/G ratio of 0.25 and a beta of 0.51.

Institutional Investors Weigh In On Takeda Pharmaceutical

Large investors have recently bought and sold shares of the company. Millennium Management LLC increased its position in shares of Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock worth $56,239,000 after purchasing an additional 2,023,707 shares in the last quarter. FMR LLC boosted its stake in Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after buying an additional 134,407 shares in the last quarter. Managed Asset Portfolios LLC grew its holdings in shares of Takeda Pharmaceutical by 0.3% during the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock worth $23,001,000 after buying an additional 4,069 shares in the last quarter. Finally, Stifel Financial Corp raised its position in shares of Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after buying an additional 224,594 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.